MedPath

Zymeworks

πŸ‡¨πŸ‡¦Canada
Ownership
-
Employees
277
Market Cap
$822M
Website
Introduction

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

A Study of ZW191 in Participants With Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Solid Tumors
Interventions
First Posted Date
2024-08-15
Last Posted Date
2025-04-06
Lead Sponsor
Zymeworks BC Inc.
Target Recruit Count
145
Registration Number
NCT06555744
Locations
πŸ‡ΊπŸ‡Έ

Yale University, New Haven, Connecticut, United States

πŸ‡ΊπŸ‡Έ

The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio, United States

πŸ‡ΊπŸ‡Έ

NEXT Oncology, San Antonio, Texas, United States

and more 13 locations

A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers

Phase 1
Recruiting
Conditions
Mesothelin-expressing Advanced Cancers
Interventions
First Posted Date
2024-07-26
Last Posted Date
2025-04-06
Lead Sponsor
Zymeworks BC Inc.
Target Recruit Count
160
Registration Number
NCT06523803
Locations
πŸ‡ΊπŸ‡Έ

Icahn School of Medicine at Mount Sinai (ISMMS) - The Blavatnik Family-Chelsea Medical Center, New York, New York, United States

πŸ‡©πŸ‡ͺ

Universitaetsklinikum Dresden, Dresden, Germany

πŸ‡ΊπŸ‡Έ

University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 10 locations

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Phase 1
Completed
Conditions
HER2-expressing Cancers
Interventions
First Posted Date
2019-01-29
Last Posted Date
2025-01-29
Lead Sponsor
Zymeworks BC Inc.
Target Recruit Count
112
Registration Number
NCT03821233
Locations
πŸ‡°πŸ‡·

Korea University Anam Hospital, Seoul, Korea, Republic of

πŸ‡¨πŸ‡¦

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

πŸ‡ΊπŸ‡Έ

City of Hope, Duarte, California, United States

and more 13 locations
Β© Copyright 2025. All Rights Reserved by MedPath